{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:01:44Z","timestamp":1791414104588,"version":"4.3.3"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,6,17]]},"abstract":"<jats:p>\n            Nontuberculous mycobacterial (NTM) infections are increasing globally.\n            <jats:named-content content-type=\"genus-species\">Mycobacterium avium<\/jats:named-content>\n            complex (MAC) and\n            <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n            complex are the most commonly reported NTM. Oral treatment options are limited, especially for the\n            <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n            complex.\n          <\/jats:p>","DOI":"10.1128\/aac.00079-21","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T11:47:52Z","timestamp":1618314472000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of\n            <i>In Vitro<\/i>\n            Susceptibility of Delafloxacin with Ciprofloxacin, Moxifloxacin, and Other Comparator Antimicrobials against Isolates of Nontuberculous Mycobacteria"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-1169","authenticated-orcid":true,"given":"Barbara A.","family":"Brown Elliott","sequence":"first","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Mycobacteria\/Nocardia Laboratory, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard J.","family":"Wallace","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Mycobacteria\/Nocardia Laboratory, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201804-236OC"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.02.013"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1620243"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2014.10.002"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05030-11"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1099\/ijsem.0.002457"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1099\/00207713-51-5-1751"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1510.090310"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00198-16"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1125"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC"},{"key":"e_1_3_2_14_2","volume-title":"Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes, 3rd ed. CLSI Standard Document, M24. CLSI, Wayne, PA.","edition":"3"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.05.002"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.34.1.65"},{"key":"e_1_3_2_17_2","first-page":"662","article-title":"BaxdelaTM (Delafloxacin): a novel fluoroquinolone for the treatment of acute bacterial skin and skin structure infections","volume":"43","author":"Adler A","year":"2018","unstructured":"Adler A, Chaudhry S, Goldberg T. 2018. BaxdelaTM (Delafloxacin): a novel fluoroquinolone for the treatment of acute bacterial skin and skin structure infections. P T 43:662\u2013666.","journal-title":"P T"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz514"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0198-x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S142140"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx543"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000631"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.283-286.2000"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz523"},{"key":"e_1_3_2_25_2","volume-title":"Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes, 1st ed. CLSI document, M62. CLSI Guideline, MM18. CLSI, Wayne, PA.","edition":"1"},{"key":"e_1_3_2_26_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing, 30th ed. CLSI document, M100. CLSI Guideline, MM18. CLSI, Wayne, PA.","edition":"30"},{"key":"e_1_3_2_27_2","unstructured":"FDA. 2017. BAXDELA (delafloxacin) prescribing information and medication guide. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000 208611s000lbl.pdf."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0790-5"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1079"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3283-3285.2002"},{"key":"e_1_3_2_31_2","volume-title":"Interpretive criteria for identification of bacteria and fungi by targeted DNA sequencing","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Interpretive criteria for identification of bacteria and fungi by targeted DNA sequencing, 3rd ed. CLSI Guideline, MM18. CLSI, Wayne, PA.","edition":"3"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.12.5699-5708.2003"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00079-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00079-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:07:46Z","timestamp":1645484866000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00079-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6,17]]}},"alternative-id":["10.1128\/AAC.00079-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.00079-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"2021-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00079-21"}}